Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor
Journal of Cystic Fibrosis · 2025-11 · 24 (6) · 1090-1093
DOI: 10.1016/j.jcf.2025.07.013 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cystic Fibrosis, 2025-11. Verfasst von Haley Haskett und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: hasketth@chop.edu. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction leads to progressive exocrine pancreatic insufficiency, resulting in difficulty in the secretion of digestive enzymes and subsequent malabsorption of nutrients. Case reports have described preserved pancreatic function with prenatal elexacaftor/tezacaftor/ivacaftor (ETI) exposure. However, little is known about pancreatic function and injury as ETI exposure decreases postnatally. Here, we discuss four infants with cystic fibrosis (CF) who were prenatally exposed to ETI, with pancreatic function ranging from preserved to mild insufficiency. All four developed elevated serum lipase, a marker of pancreatic cell injury, as ETI exposure diminished after birth. These cases illustrate the relationship between sweat chloride as a biomarker of CFTR function, fecal elastase as a biomarker of pancreatic function, and serum lipase a biomarker of pancreatic cell injury. While prenatal ETI exposure can preserve pancreatic function in infants with CF, ongoing postnatal ETI exposure may be necessary to prevent pancreatic damage, suggesting a role for early ETI therapy in prenatally exposed infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Electronic address: hasketth@chop.edu.
- Division of Pulmonary and Sleep Medicine, SUNY Upstate Medical Center, Syracuse, NY, USA.
- Division of Pulmonary and Sleep Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Förderung
- Cystic Fibrosis Foundation
Zitieren
APA
Haskett, H., Fortner, C., Shanley, L., & Ren, C. L. (2025). Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis, 24(6), 1090-1093. https://doi.org/10.1016/j.jcf.2025.07.013
Vancouver
Haskett H, Fortner C, Shanley L, Ren CL. Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor. Journal of Cystic Fibrosis. 2025;24(6):1090-1093. doi:10.1016/j.jcf.2025.07.013
BibTeX
@article{Haskett2025,
author = {Haskett, Haley and Fortner, Christopher and Shanley, Laura and Ren, Clement L},
title = {Elevated serum lipase in infants with cystic fibrosis exposed to prenatal and postnatal elexacaftor/tezacaftor/ivacaftor},
journal = {Journal of Cystic Fibrosis},
year = {2025},
volume = {24},
number = {6},
pages = {1090--1093},
doi = {10.1016/j.jcf.2025.07.013}
}
EUVIMED